Exploration of novel therapies for treatment of allergic diseases has highlighted measures which decrease IgE levels and target cytokines (e.g., IL-4, IL-5, and IL-31) thought to be implicated in control of those levels and other cell populations (eosinophils/basophils) implicated in allergic disease [18, 24–30]. Here, IL31 is linked to allergic disease.